207 ( 1 ) Cefditoren pivoxil G 2010 2 2 2006 3 Cefditoren pivoxil CDTR-PI MS 10% CDTR-PI 305 2,144 2,006 1,958 1.79% 36 2,006 26 (1.30%) CDTR-PI CDTR-PI (9 mg/kg/day) 1.5 2 (2.70%) 2 (1.92%) 93.5% 1,831 1,958 832 1,217 Streptococcus pneumoniae 89.7% Haemophilus influenzae 90.3% Moraxella catarrhalis 92.2% 427 577 S. pneumoniae 83.3% H. influenzae 87.1% M. catarrhalis 88.9% (PISP) 88.0% (PRSP) 90.1% b- (BLNAR) 92.5% PISP 85.7% PRSP 77.5% BLNAR 81.8% 8 8 8 457 1 13.5 mg/kg 13.5 mg/kg
208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) 2 1994 4 100 1998 2 2004 2 MS 2 2008 12 MS 10% 1994 2000 6 2006 3 1 2009 2009 2006 CDTR-PI (PRSP) (PISP) b- (BLNAR) (GPSP) 16 12 20 171 I. 1. MS 10% 1g CDTR-PI 100 mg 2. 15 3. 2006 7 2008 6 2 4. 5 Fax 5.
209 ( 3 ) 1. 1 6. 2006 1 7. 1 100 (%) ICH (MedDRA/J) (Ver.11.1) 2 2 100 (%) 100 (%) 8. c 2 5% Mantel Haenszel (Stepwise)
210 ( 4 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 1. II. 1. 305 2,144 1 2,144 4 1 123 4 7 138 2,006 2,006 1 47 48 1,958 2. 2,006 2-1, 2 1 14 3 1 3 3 90% 52.1% 40.0% 803 2,006 13.2% 265 2,006 8.5% 170 2,006 0.2% 5 2,006 8.8% Clavulanate/Amoxicillin (CVA/AMPC) 2.4% 49 2,006 Amoxicillin (AMPC) 2.0% 40 2,006 Cefcapene pivoxil (CFPN-PI) 1.5% 31 2,006 Clarithromycin (CAM) 1.2% 24 2,006 94.1% 70.7% 1,419 2,006 42.9% 861 2,006
211 ( 5 ) 42.6% 855 2,006 1 10.0 mg/kg 9 mg/kg 7 2,006 1 3 5 5 1 1 5 2-1.
212 ( 6 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 2-2. 6 10 3. 1 2,006 4 36 38 1.79% 26 1.30% 68.4% 26 38 38 5 1 3 55.3% 21 38 94.7% 36 38
213 ( 7 ) 3. 1 4. 8 2 75% 27 36 7 12 2 6 0 6 1 13.5 mg/kg 18 mg/kg
214 ( 8 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 5.
215 ( 9 ) 6. 42.9% 861 2,006 8 53.8% 14 26 3 2 70.8% 17 24 7 5 26 12 13 1 2 5 12 1 13 2 1 10 4. 1 1,958 93.5 1,831 1,958 2 1,958 49.3% 965 1,958 832 1,217 Streptococcus pneumoniae 397 Haemophilus influenzae 393 Moraxella catarrhalis 166 261 3 S. pneumoniae H. influenzae M. catarrhalis 78.6% 956
216 ( 10 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 7. 1,217 S. pneumoniae (PISP PRSP) 58.9% 234 397 H. influenzae (BLNAR BLPAR BLPACR) 28.0% 110 393 BLNAR 27.2%: 107 393 7 S. pneumoniae 89.7% H. influenzae 90.3% M. catarrhalis 92.2% PISP 88.0% PRSP 90.1% BLNAR 92.5% 1 3 1,958 8 4
217 ( 11 ) 8.
218 ( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 9. 8 8 8 8 8 457 1 1 4.3 mg/kg 33.3 mg/kg 9 mg/kg 1.5 13.5 mg/kg 1.5 13.5 mg/kg 1 9 1 2 2 5 6 1 13.5 mg/kg 13.5 mg/kg (p 0.0452) 1 8 0 348 2 1 13.5 mg/ kg 13.5 mg/kg (p 0.0438) 5. 427 577 10 S. pneumoniae 83.3% H. influenzae 87.1% M. catarrhalis 88.9% PISP 85.7% PRSP 77.5% BLNAR 81.8% III. 2)
219 ( 13 ) 10. 3) 2006 1) 2009 4) 5) 305 2,144 1. 2,006 36 38 1.79% 36 2,006 2.35% 136 5,783 68.4% 26 38 1.30% 26 2,006
220 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 26 0 1 6) (1.97%) (0.79%) 0 4% 1.5 13.5 mg/ kg 18 mg/kg 3% 7) 8) 42.9% 2. 93.5% 1,831 1,958 94.3% 543 576 S. pneumoniae 89.7% PISP 88.0% PRSP 90.1% H. influenzae 90.3% BLNAR 92.5% 90% S. pneumoniae H. influenzae M. catarrhalis 92.2% 1,217 S. pneumoniae 32.6% 397 1,217 H. influenzae 32.3% 393 1,217 M. catarrhalis 13.6% 166 1,217 3 S. pneumoniae H. influenzae M. catarrhalis 78.6% 2009 2007 4 9) S. pneumoniae 34.1% H. influenzae 24.2% M. catarrhalis 4.4% 2 95% 2 0 1 87.3% 88.5% 2006 3 3 2009 10 2 24 2009
221 ( 15 ) 8 79% 93.7% 86.0% 94.2% 91.5% 90% c 2 2 27.0% 389 1,441 42.1% 217 516 37.6% 542 1,441 75.2% 388 516 c 2 P 0.0001 86.7% 1 8 8 457 2 2 5 6 1 13.5 mg/kg 13.5 mg/kg 8 0 348 1 13.5 mg/kg 13.5 mg/kg S. pneumoniae 83.3% H. influenzae 87.1% M. catarrhalis 88.9% PISP 85.7% PRSP 77.5% BLNAR 81.8% PRSP 3
222 ( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 CDTR-PI 1) 27: 71 107, 2006 2) 55: 201 210, 2007 3) JOHNS 24: 17 20, 2008 4) Jpn. J. Antibiotics 54 (Suppl.B): 37 38, 2001 5) Otol. Jpn. 17: 627 637, 2007 6) 14: 1000 1007, 1998 7) AMPC/CVA (14: 1) 3 26: 189 195, 2008 8) Jpn. J. Antibiotics 60: 221 241, 2007 9) 4 26: 15 26, 2008 10) 2009 30 34 2009 Evaluation of the safety and efficacy of cefditoren pivoxil fine granules for pediatric use in pediatric patients with acute otitis media SAORI KAWAMATA, HITOSHI YAMADA and YOSHIKAZU SATO Pharmacovigilance Dept. Reliability & Quality Assurance Center, Meiji Seika Kaisha, Ltd. YUJI SASAGAWA, YASUHIRO IWAMA and MASATO MATUMOTO Biostatistics & Data Management Clinical Data Science Dept., Pharmaceuticals, Meiji Seika Kaisha, Ltd. A Clinical Practice Guideline for the Diagnosis and Management of Acute Otitis Media in Children, in view of the causative organisms of the disease and their drug susceptibility, was issued in March 2006.
223 ( 17 ) In the guideline, cefditoren pivoxil (CDTR-PI, Meiact MS fine granules 10% for pediatric use) is recommended as an oral cephem antibiotic for the treatment of the disease. To collect information on the appropriate use of the drug in the clinical setting after issuance of the guideline, we conducted a specific postmarketing study of CDTR-PI in pediatric patients with acute otitis media. With this study, 2144 patients were enrolled in 305 medical institutions. Of them, 2006 and 1958 patients were chosen for safety and efficacy analysis, respectively. The incidence of adverse drug reactions was 1.79% (36/2006 patients). No unexpected or serious adverse drug reactions were reported by this study. The most common adverse drug reaction was diarrhea, which was reported in 26 cases (1.30%). The symptom resolved or subsided during CDTR-PI therapy or after discontinuation or completion of the therapy in all cases. The incidence of diarrhea in patients treated with CDTR-PI at 1.5- to 2-fold the usual dose was 2.70%, which was slightly higher than the usual dose, but that in patients more than 2-fold the usual dose was 1.92% which was not higher than 1.5- to 2-fold the usual dose. The incidence of diarrhea itself was not substantially high. Concerning the clinical efficacy of CDTR-PI, the response rate was 93.5% (1831/1958 patients). Among 1217 strains from whom 832 patients were detected as causative organisms at baseline bacteriological examination, the response rate by causative organism was 89.7% for Streptococcus pneumoniae, 90.3% for Haemophilus influenzae, and 92.2% for Moraxella catarrhalis. Among documented eradication of 577 strains with 427 patients, the bacterial eradication rate by causative organism was 83.3% for S. pneumoniae, 87.1% for H. influenzae, and 88.9% for M. catarrhalis. For each major resistant strain, the response rate was 88.0% for penicillin-intermediate S. pneumoniae (PISP), 90.1% for penicillin-resistant S. pneumoniae (PRSP), and 92.5% for b-lactamase negative ampicillin-resistant H. influenzae (BLNAR), while the bacterial eradication rate was 85.7% for PISP, 77.5% for PRSP, and 81.8% for BLNAR. In addition, 457 patients without myringotomy and tympanic swelling or otorrhea rated as a severity score of 8 (symptoms emphasized in the guideline) were selected as a subpopulation allowing us to define the dose-efficacy relationship more clearly. In this subpopulation, the relationship between the dose and the efficacy of CDTR-PI was assessed. The assessment revealed that the response rate was significantly higher in patients with a mean daily dose of at least 13.5 mg/kg than in those with a mean daily dose below13.5 mg/kg. In summary, CDTR-PI raised no noteworthy concerns about its safety or efficacy in pediatric patients with acute otitis media. These findings reconfirm the usefulness of the drug.